ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric heart failure and risk factors. Key takeaway: Mavacamten Remodels HCM Long-Term: VALOR-HCM Data.
Article Links:
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. (JACC. Cardiovascular imaging)
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. (Cardiology)
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis. (International journal of cardiology)
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure. (International journal of cardiology)
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/
Featured Articles
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956275
Summary: In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947836
Summary: This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40414542
Summary: A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40412628
Summary: This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40409500
Summary: This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.
Transcript
Today’s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.
Article number two. Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.
Article number three. Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis. A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.
Article number four. The efficacy and safety of dapagliflozin in pediatric heart failure. This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.
Article number five. Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.
Thank you for listening. Don’t forget to subscribe.
Keywords
pediatric heart failure, risk factors, implantable cardiac monitor, REMOVE trial, VALOR-HCM trial, left ventricular outflow tract gradient, mavacamten, right atrial strain, nomogram, hemoadsorption, dapagliflozin, device-detected atrial fibrillation, sex differences, elderly patients, cardiac surgery, cryptogenic stroke, mortality, frailty syndrome, infective endocarditis, Sodium-Glucose Cotransporter-2 inhibitor, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, cardiac remodeling, heart transplantation, left atrial strain.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25 first appeared on Cardiology Today.
Article Links:
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. (JACC. Cardiovascular imaging)
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. (Cardiology)
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis. (International journal of cardiology)
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure. (International journal of cardiology)
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. (International journal of cardiology)
Full episode page: https://podcast.explainheart.com/podcast/mavacamten-remodels-hcm-long-term-valor-hcm-data-09-17-25/
Featured Articles
Article 1: Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.
Journal: JACC. Cardiovascular imaging
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956275
Summary: In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.
Article 2: Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model.
Journal: Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40947836
Summary: This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.
Article 3: Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40414542
Summary: A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.
Article 4: The efficacy and safety of dapagliflozin in pediatric heart failure.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40412628
Summary: This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.
Article 5: Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor.
Journal: International journal of cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40409500
Summary: This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.
Transcript
Today’s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial. In patients with severely symptomatic obstructive hypertrophic cardiomyopathy eligible for septal reduction therapy, treatment with mavacamten resulted in sustained reductions in left ventricular outflow tract gradients and favorable cardiac remodeling effects over 128 weeks. These findings from the VALOR-HCM trial suggest mavacamten provides a durable, non-invasive option for managing obstructive hypertrophic cardiomyopathy.
Article number two. Analysis of risk factors for frailty syndrome in elderly patients with acute coronary syndrome and establishment of a nomogram prediction model. This study retrospectively analyzed elderly patients with acute coronary syndrome to identify risk factors for frailty syndrome. A nomogram prediction model was established based on these risk factors to predict the likelihood of frailty syndrome in elderly acute coronary syndrome patients.
Article number three. Sex differences on the effect of hemoadsorption during cardiac surgery – A REMOVE trial post-hoc analysis. A post-hoc analysis of the REMOVE trial, which examined the use of hemoadsorption during cardiac surgery for infective endocarditis, revealed sex-based differences in outcomes. The study aimed to evaluate if there is a sex-specific impact of hemoadsorption during cardiac surgery for infective endocarditis.
Article number four. The efficacy and safety of dapagliflozin in pediatric heart failure. This observational study evaluated the efficacy and safety of dapagliflozin in pediatric patients with heart failure. The primary outcome was a composite of worsening heart failure, heart transplantation, and mortality; the study provides initial data on the use of Sodium-Glucose Cotransporter-2 inhibitors in a pediatric population.
Article number five. Predictive value of left and right atrial strain for the detection of device-detected atrial fibrillation in patients with cryptogenic stroke and implantable cardiac monitor. This study investigated the relationship between left and right atrial strain parameters, measured by speckle-tracking echocardiography, and the occurrence of device-detected atrial fibrillation in patients with cryptogenic stroke who received implantable cardiac monitors. The findings suggest that atrial strain parameters may help predict the risk of device-detected atrial fibrillation in this population.
Thank you for listening. Don’t forget to subscribe.
Keywords
pediatric heart failure, risk factors, implantable cardiac monitor, REMOVE trial, VALOR-HCM trial, left ventricular outflow tract gradient, mavacamten, right atrial strain, nomogram, hemoadsorption, dapagliflozin, device-detected atrial fibrillation, sex differences, elderly patients, cardiac surgery, cryptogenic stroke, mortality, frailty syndrome, infective endocarditis, Sodium-Glucose Cotransporter-2 inhibitor, obstructive hypertrophic cardiomyopathy, acute coronary syndrome, cardiac remodeling, heart transplantation, left atrial strain.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Mavacamten Remodels HCM Long-Term: VALOR-HCM Data 09/17/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust